Development of a stable single-vial liposomal formulation for vincristine
Open Access
- 1 June 2019
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 14, 4461-4474
Abstract
Background: Vincristine is a potent therapeutic agent with well-defined activity against hematologic malignancies and solid tumors. It is a cell-cycle specific drug with concentration and exposure duration dependent activity. When used by liposomal delivery, it exhibits enhanced anti-tumor activity. However, vincristine liposome formulation in the clinic is supplied as a 3-vial-kit due to lacking sufficient stability. So it has to be prepared in situ prior to use through a multi-step process. Purpose: The purpose here is to develop a more stable and ready-to-use liposomal formulation for vincritstine in one vial. Patients and methods: A series of preparations were investigated based on sphingomyelin/cholesterol/PEG2000-DSPE lipid composition, with different drug/lipid (D/L) ratios (1/10, 1/5, 1/2), using an active sucrose octasulfate triethylamine salt gradient loading method. In this work, compared to generic vincristine sulfate liposome injection (GVM), the stability both in vivo and in vitro and efficacy in vivo of novel vincristine liposomes were investigated. Results: It was shown that the degradation of vincristine during 2–8°C storage was significantly decreased from 8.2% in 1 month (GVM) to 2.9% in 12 months (D/L ratio 1/5). The half-time for sphingomyelin/cholesterol/PEG2000-DSPE liposomes in vivo could be adjusted from 17.4 h (D/L ratio 1/10) to 22.7 h (D/L ratio 1/2) in rats, while the half-time for GVM was only 11.1 h. The increase in drug retention contributed to the lower in vivo toxicity. The antitumor efficacy was evaluated using a human melanoma tumor model and showed remarkable improvement compared to GVM. Conclusion: The study demonstrates that the new formulation with the drug/lipid ratio of 1/5 owns a higher encapsulation efficiency, better stability, lower toxicity and superior antitumor efficacy, which is screened out for further development.Keywords
This publication has 30 references indexed in Scilit:
- Vincristine-loaded liposomes prepared by ion-paring techniques: Effect of lipid, pH and antioxidant on chemical stabilityEuropean Journal of Pharmaceutical Sciences, 2018
- Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristineCancer Chemotherapy and Pharmacology, 2012
- Vincristine Sulfate Liposome InjectionBioDrugs, 2012
- Vincristine: Can its therapeutic index be enhanced?Pediatric Blood & Cancer, 2009
- Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drugExpert Opinion on Biological Therapy, 2006
- The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activityCancer Chemotherapy and Pharmacology, 1996
- Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour modelsBritish Journal of Cancer, 1995
- Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenograftsBiochemical Pharmacology, 1988
- Catharanthus Alkaloids. XXXIV. Catharanthamine, A New Antitumor Bisindole Alkaloid From Catharanthus roseusJournal of Natural Products, 1981
- Clinical Studies with VincristineBlood, 1963